Antibiotics for the treatment of hepatic encephalopathy (Q27012878)

ChEBI release 2020-05-28

ChEBI ID

75246

hepatic encephalopathy

1 reference

2

Jasmohan S. Bajaj

1 reference

Kavish R. Patidar

1

1 reference

language of work or name

1 reference

June 2013

1 reference

published in

Metabolic Brain Disease

1 reference

volume

28

1 reference

page(s)

307-12

1 reference

issue

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11011-013-9383-5

exact match

0 references

cites work

Rifaximin treatment in hepatic encephalopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

A current review of the diagnostic and treatment strategies of hepatic encephalopathy

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Mechanisms, diagnosis and management of hepatic encephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Review article: the modern management of hepatic encephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Severe sepsis in cirrhosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Review article: the burden of hepatic encephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Rifaximin: in vitro and in vivo antibacterial activity--a review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Treatment of hepatic encephalopathy with metronidazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Rifaximin for the treatment of hepatic encephalopathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Metronidazole pharmacokinetics in patients with hepatic encephalopathy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

31 May 2018

Drug therapy: rifaximin

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

21 January 2018

Hepatic Encephalopathy.

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9383-5

Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654040

Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study

28 November 2018

1 reference

12 December 2020

Durability of rifaximin response in hepatic encephalopathy

1 reference

12 December 2020

Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study

1 reference

12 December 2020

Outcomes in adult and pediatric liver transplantation among various ethnic groups

1 reference

12 December 2020

A non-absorbable rifamycin for treatment of hepatic encephalopathy

1 reference

12 December 2020

Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites

1 reference

12 December 2020